Join to View Full Profile
44 Binney StDana 710-CBoston, MA 02115
Phone+1 617-582-8598
Dr. Freedman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2002
University of Pennsylvania Health SystemResidency, Internal Medicine, 1996 - 1998
University of Michigan Medical SchoolClass of 1996
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2011
Publications & Presentations
PubMed
- The Germline and Somatic Origins of Prostate Cancer Heterogeneity.Takafumi N Yamaguchi, Kathleen E Houlahan, Helen Zhu, Natalie Kurganovs, Julie Livingstone
Cancer Discovery. 2025-05-02 - 1 citationsIncreased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.Larysa Poluben, Mannan Nouri, Jiaqian Liang, Shaoyong Chen, Andreas Varkaris
Cell Reports. 2025-01-28 - 1 citationsDecoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription.Umut Berkay Altıntaş, Ji-Heui Seo, Claudia Giambartolomei, Dogancan Ozturan, Brad J Fortunato
Nature Communications. 2024-11-03
Press Mentions
Prostate Cancer Metastasis Linked to Revival of Dormant Molecular ProgramJuly 19th, 2020
Grant Support
- Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-makingDANA-FARBER CANCER INST2025–2030
- Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
- Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2022–2027
- Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2022–2027
- Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
- Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
- Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
- Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesDANA-FARBER CANCER INST2021–2026
- P-2: Genetic And Clinical Characterization Of The 8q24 Prostate Cancer Risk LocusNational Cancer Institute2010–2011
- Elucidating Loci Involved In Prostate Cancer SuceptibilityNational Cancer Institute2010–2011
- Discovery, Biology And Risk Of Inherited Variants In Breast CancerNational Cancer Institute2010–2011
- Genetic And Clinical Characterization Of The 8q24 Prostate Cancer Risk LocusNational Cancer Institute2007–2009
- FINE Mapping And Characterization Of The 8q24 Prostate Cancer Risk LocusNational Cancer Institute2007–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
